Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2023-07-31 Investor Presentation
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
INOVIQ Investor Briefing 28 pages 1.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by INOVIQ Limited dated 1 August 2023, containing extensive information about the company's technology, products, clinical study data, market positioning, and future plans. It includes scientific rationale, clinical validation study results, product pipeline, and market strategy. The content is structured as a presentation with slides, charts, and detailed explanations aimed at investors or stakeholders. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a voting or dividend announcement. The document is clearly a detailed investor presentation focusing on financials, strategy, and market position. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-07-31 English
Appendix 4C and Quarterly Activities Report - June 2023 10 pages 614.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4C & QUARTERLY BUSINESS UPDATE Period Ended 30 June 2023' and contains detailed quarterly financial data including cash flow statements, operating cash receipts, and expenditures. It also includes business updates, R&D progress, and commercial updates for the quarter ended 30 June 2023. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed companies, confirms this is a quarterly financial report. The document is comprehensive and contains substantive financial data and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the correct classification is Interim / Quarterly Report (IR). Q4 2023
2023-07-27 English
INOVIQ and Promega announce Global Joint Marketing Agreement 4 pages 288.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing a global joint marketing agreement between INOVIQ and Promega for exosome isolation and nucleic acid purification solutions. It details the terms of the marketing agreement, the companies involved, their products, and market context. There is no financial data, no regulatory filing references, no voting results, no management or board changes, no earnings or interim report data, and no audit or legal proceedings information. The document is a corporate announcement about a partnership and marketing collaboration, not a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other categories.
2023-07-05 English
SubB2M Breast Cancer Test Results Webinar Recording 1
Investor Presentation Classification · 95% confidence The document is a brief announcement about the availability of a recording of an online investor briefing (webinar) held on 29 June 2023. It mentions that the presentation was lodged with ASX on 29 June 2023 and provides a link to the recording. The content includes a summary of the webinar topics and contact information but does not contain any financial statements, detailed financial data, or regulatory filings. The document length is short (2695 characters) and it primarily serves to inform investors about the availability of the webinar recording and presentation. This fits the profile of an Investor Presentation (IP) rather than a full report or earnings release. Therefore, the appropriate classification is Investor Presentation (IP).
2023-07-02 English
Notification of cessation of securities - IIQ 4 pages 23.8KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Notification of cessation of +securities' and details the lapse of certain options (securities) for INOVIQ LTD. It provides specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is an announcement about changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement related to changes in the company's capital structure, specifically cessation of securities. This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes including cessation or lapsing of securities. The document length is 3675 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is SHA with high confidence.
2023-06-29 English
SubB2M/CA15.3 Clinical Validation Data Investor Presentation 20 pages 1.6MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by INOVIQ Limited dated 29 June 2023, focusing on clinical validation data for their SubB2M/CA15-3 breast cancer test. It includes company background, product pipeline, clinical study design, and results with detailed data and charts. The content is structured as a presentation with forward-looking statements, disclaimers, and detailed scientific and financial information aimed at investors. There is no indication that this is a regulatory filing, earnings release, or an official report like an annual or interim report. The document is clearly a detailed investor presentation focusing on product development, clinical validation, and company strategy. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-06-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.